IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: A phase I dose-escalation study

被引：0
|
作者：
Liu, Rujiao
Hu, Xichun
Song, Zhengbo
Zhang, Jian
Jin, Jianan
Gao, Shuiping
Sun, Yuping
Zhang, Yan
Gao, Shegan
Jia, Ruinuo
Jing, Deqiang
Xu, Yu
Wang, Zhenjiu
Lu, Qiying
Tian, Wenzhi
Cheng, Xiangdong
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Shandong Prov Inst Canc Prevent & Treatment, Jinan, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[5] ImmuneOnco Biopharmaceut Shanghai Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14506
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anti-PD-1/TGF-βRII bispecific antibody fusion protein LBL-015 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose-escalation study
    Li, Qun
    Zhao, Wei
    Wang, Wei
    Chen, Po
    Niu, Zuoxing
    Ni, Shuqin
    Luo, Suxia
    Qiao, Junjing
    Wang, Mingxi
    Li, Yong
    He, Yan
    Liu, Tao
    Li, Tao
    Cai, Shengli
    Li, Jin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.
    Sanborn, Rachel E.
    Bordoni, Rodolfo Eduardo
    Fleming, Gini F.
    Khasraw, Mustafa
    Hawthorne, Thomas
    Thomas, Lawrence J.
    Rawls, Tracey
    Young, Diane C.
    Golden, Philip
    Keler, Tibor
    Yellin, Michael Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.
    Xu, Jian-Ming
    Qin, Shukui
    Zhang, Yun
    Zhang, Yaoyue
    Jia, Ru
    Liu, Rongrui
    Zhang, Gairong
    Zhao, Chuanhua
    Lu, Ni
    Liu, Huilong
    Xu, Wenlian
    Fu, Meng
    Cao, Walt
    Lu, Haolan
    Liu, David
    Dong, Ruiping
    Wang, Xiaoxiao
    Wang, Pilin
    Xu, Ting
    Gong, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors
    Angevin, Eric
    Tabernero, Josep
    Elez, Elena
    Cohen, Steven J.
    Bahleda, Rastilav
    van Laethem, Jean-Luc
    Ottensmeier, Christian
    Lopez-Martin, Jose A.
    Clive, Sally
    Joly, Florence
    Ray-Coquard, Isabelle
    Dirix, Luc
    Machiels, Jean-Pascal
    Steven, Neil
    Reddy, Manjula
    Hall, Brett
    Puchalski, Thomas A.
    Bandekar, Rajesh
    de Velde, Helgi van
    Tromp, Brenda
    Vermeulen, Jessica
    Kurzrock, Razelle
    CLINICAL CANCER RESEARCH, 2014, 20 (08) : 2192 - 2204
  • [25] A phase I/IIa first-in-human study of PM1003 (anti-PD-L1 x 4-1BB bispecific antibody) in patients with advanced solid tumors
    Xue, J.
    Sun, Y.
    Li, D.
    Guo, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S629 - S629
  • [26] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [27] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [28] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [29] Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
    Doz, Francois
    Locatelli, Franco
    Baruchel, Andre
    Blin, Nicolas
    De Moerloose, Barbara
    Frappaz, Didier
    Dworzak, Michael
    Fischer, Matthias
    Stary, Jan
    Fuertig, Rene
    Riemann, Kathrin
    Taube, Tillmann
    Reinhardt, Dirk
    PEDIATRIC BLOOD & CANCER, 2019, 66 (10)
  • [30] A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1) IN PATIENTS WITH ADVANCED SOLID TUMORS: INITIAL DOSE-ESCALATION RESULTS
    Johnson, Melissa
    Lakhani, Nehal
    Girda, Eugenia
    Olszanski, Anthony
    Fong, Lawrence
    Han, Hyunsil
    Casey, Kerry
    Li, Siyu
    Visich, Jennifer
    Skokos, Dmitris
    Seebach, Frank
    Lowy, Israel
    Fury, Matthew
    Mathias, Melissa
    Segal, Neil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A767 - A768
12345